Celgene Research Programs - cFMS, TYK2, PDGFR: Celgene announced progress on three partnered research programs in April 2010 on which Array is conducting research: cFMS (oncology), TYK2 (inflammation) and PDGFR (fibrosis). Celgene reported that all three programs have the possibility of entering clinical development over the next 12 to 24 months. Under the terms of Array's agreement with Celgene, Celgene has the option to select two of the programs and Array would retain rights to the third program.

Genentech collaboration: Genentech announced that GDC-0068 / RG7440, an AKT inhibitor discovered by Array and Genentech scientists, advanced into a Phase 1 dose escalation study in cancer patients.

InterMune announces positive danoprevir (RG7227 and ITMN-191) results: InterMune, Inc. announced in April 2010 top-line results from a planned interim analysis of the Phase 2b randomized, partially-blind study evaluating the hepatitis C virus NS3/4A protease inhibitor danoprevir, also known as RG7227 / ITMN-191, which was coinvented by Array and InterMune. Danoprevir was administered at either 300 mg three times daily, 600 mg twice daily or 900 mg twice daily for 12 weeks in combination with PEGASYS?® (pegylated interferon alfa-2a) and COPEGUS?® (ribavirin), compared with placebo for the same duration plus PEGASYS and COPEGUS. In November 2009, InterMune reported that due to a safety signal, dosing in the 900 mg group had been stopped. InterMune reported that results from the study indicate danoprevir plus PEGASYS and COPEGUS are capable of achieving complete early virologic response rates as high as 90 percent, compared to 43 percent in the placebo group.

Array advanced all four clinical programs for the treatment of cancer according to plan: ARRY-520 - KSP inhibitor for MM: Array completed enrollment in a Phase 1 trial with ARRY-520, a novel KSP inhibitor, in patients with solid tumors and in a Phase 1/2 trial in patients with acute myelogenous leukemia. We are initiating two Phase 1b combination studies in patients with MM.

ARRY-614 - p38/Tie-2 Inhibitor for MDS: Array continued dosing patients with myelodysplastic syndrome in a Phase 1 trial of ARRY-614 to determine the safety, maximum tolerated dose, pharmacokinetics and to obtain preliminary efficacy data of the compound in this patient population.

ARRY-543 - HER2/EGFR inhibitor for solid tumors: Array completed enrollment in three Phase 1b trials of ARRY-543 in combination with Xeloda?® (capecitabine), Taxotere and Gemzar?® (gemcitabine), respectively. The maximum tolerated dose of ARRY-543 was achieved in each trial the prior quarter. Trial results will be disclosed at an appropriate scientific conference over the next year.

ARRY-380 - HER2 oral, selective inhibitor for cancer: Array reached the maximum tolerated dose in a Phase 1 trial of ARRY-380 to evaluate the safety, maximum tolerated dose and pharmacokinetics in patients with advanced cancer. Array is expanding the trial at the maximum tolerated dose in patients with HER2 positive cancer.

Financial Performance - Fiscal 2010 Compared to Fiscal 2009:

Revenue - $53.9 million vs. $25.0 million, an increase of $28.9 million Net Loss - $77.6 million vs. $127.8 million, an improvement of $50.2 million Loss Per Share - $1.55 vs. $2.67, an improvement of $1.12 Net Cash Flow from Operations - $17.6 million vs. ($92.9) million, an improvement of $110.5 million Cash and Marketable Securities at year end - $128.9 million vs. $57.5 million, an increase of $71.4 million

SOURCE Array BioPharma Inc.